# Psilocybin for Treatment-Resistant Depression

> **NCT06230757** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 40 (estimated)

## Conditions studied

- Major Depressive Disorder
- Anhedonia
- Treatment Resistant Depression

## Interventions

- **DRUG:** Psilocybin 25mg
- **DRUG:** Placebo (active placebo)

## Key facts

- **NCT ID:** NCT06230757
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-08
- **Primary completion:** 2026-03-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06230757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06230757, "Psilocybin for Treatment-Resistant Depression". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06230757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*